FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
49 letters match. Newest first.
-
AnimalNeogen Corporation
FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsSante Manufacturing Inc.
Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsRevlon Group Holdings, LLC
FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.
High risk -
DrugsGC America, Inc.
FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
High risk -
DrugsIntegrity Partners Group
FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.
High risk -
DrugsPrivate Label Skin Care, Inc.
FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsRhyz Analytical Labs
FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.
High risk -
DrugsChromatography Institute of America dba Compounder’s International Analytical Laboratory
FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.
High risk -
DevicesCCIC Huatongwei International Inspection Co., Ltd.
FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsZhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.
FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
High risk -
DrugsAnalytical Food Laboratories, Inc.
FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.
High risk -
DrugsOmni Lens Pvt. Ltd.
FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
High risk -
DrugsWittman Pharma, Inc.
FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.
High risk -
DrugsGreco Gas, Inc.
Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.
High risk -
DrugsARG Laboratories, Inc.
FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.
High risk -
DrugsOptikem International Inc.
FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.
High risk -
DrugsSani-Care Salon Products, Inc.
FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.
High risk -
DrugsCohere Beauty
FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.
Medium -
DrugsMaster Paints & Chemicals Corp.
FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
High risk -
DrugsHigley Industries, Inc.
FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.
High risk -
DrugsBell International Laboratories, Inc.
Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.
High risk -
DrugsLightEyez Limited
LightEyez eye drops sold in the U.S. were contaminated with microbes, and FDA cited unapproved new drug claims for its eye drops.
High risk -
DrugsSichuan Deebio Pharmaceutical Co. Ltd.
FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.
High risk -
DrugsPrime Lab LLC
Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.
High risk -
DrugsInopak, Ltd.
Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.
High risk -
DrugsNational Chemical Laboratories
National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.
High risk -
DrugsElemental Herbs Inc. d/b/a ALL good
Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.
High risk -
DrugsHandock Cosmetics Co., Ltd.
FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.
High risk -
DrugsLCC Ltd.
LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.
High risk -
DrugsSuhan Aerosol
Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.
High risk -
DrugsFuller Industries Inc.
FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.
High risk -
DrugsDrivergent, Inc.
Drivergent's hand sanitizers had acetaldehyde and acetal above allowed limits, FDA says.
High risk -
DrugsCosmetic Science Laboratories LLC
FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.
High risk -
DrugsAuto-Chlor System LLC
Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.
High risk -
DrugsEksa Mills S.A. de C.V.
FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.
High risk -
DrugsBi-Coastal Pharma International
FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.
High risk -
DrugsColorful Products Corporation
FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.
High risk -
DrugsSpecialty Process Labs LLC
FDA warned Specialty Process Labs about manufacturing quality failures for thyroid USP active ingredient, including unvalidated processes and data control gaps.
High risk -
DrugsChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation
FDA warned Chameleon Sanitizer Corporation that its hand sanitizer was made under insanitary conditions and violated manufacturing and misbranding rules.
High risk -
DrugsSyntec Pharma Corp
FDA warned Syntec Pharma Corp, an API repackager in Farmingdale, New York, that weak cross-contamination controls and quality oversight made its drugs adulterated.
High risk -
DrugsSimex Logistics S.A. de C.V.
Mexican drugmaker Simex Logistics shipped hand sanitizer labeled 70% alcohol that tested at 51%, FDA says.
High risk